REPLIMUNE GROUP, INC. Lessee, Operating Lease, Liability, to be Paid, Year Five
REPLIMUNE GROUP, INC. (REPL) had Lessee, Operating Lease, Liability, to be Paid, Year Five of $369.00 thousand as of 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive · last filed 2026-06-29
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $369.00K.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $579.00K.
- 2024-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $1.00M.
- 2023-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $1.08M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Five |
|---|---|
| 2026-03-31 | $369.00K 10-K · filed 2026-06-29 |
| 2025-03-31 | $579.00K 10-K · filed 2025-05-22 |
| 2024-03-31 | $1.00M 10-K · filed 2024-05-16 |
| 2023-03-31 | $1.08M 10-K · filed 2023-05-18 |
| 2022-03-31 | $1.06M 10-K · filed 2022-05-19 |
| 2021-03-31 | $1.01M 10-K · filed 2021-05-20 |
| 2020-03-31 | $614.00K 10-K · filed 2020-06-03 |
| 2019-12-31 | $605.00K 10-Q · filed 2020-02-13 |
| 2019-09-30 | $605.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |